ICU sedation, delirium & recovery
Long-Term Outcome of Severe Metabolic Acidemia in ICU Patients, a BICAR-ICU Trial Post Hoc Analysis
Authors' conclusion
Long-term HRQoL was decreased in both the control and the sodium bicarbonate groups of the BICAR-ICU trial and was lower than the general population, especially in the physical domains.
Study context
- Population
- Day 28 critically ill survivors admitted with severe acidemia, enrolled in BICAR-ICU, 26 French ICUs
- Comparison
- Sodium bicarbonate vs no sodium bicarbonate infusion
- Primary endpoint
- Health-related quality of life (HRQoL; SF-36 and EuroQol 5-D questionnaires)
Methodological detailsmulticentre
- Multicentre
Primary result
As reported in the abstract
HRQoL
- Health-related quality of life (HRQoL) reduced, no significant difference between the two groups
Secondary outcomes
| Outcome | Bicarbonate | Control | P value |
|---|---|---|---|
| HRQoL, role-physical domain | 49/100 ± 43 | 64/100 ± 41 | P = 0.28 |
| HRQoL, emotional domains | 86/100 ± 34 | 96/100 ± 19 | P = 0.44 |
Functional problems among survivors
- Moderate to severe problems walking
- Forty percent
- Moderate to severe problems with usual activities
- half
- Moderate to severe anxiety or depression symptoms
- one third
HRQoL vs French general population
- HRQoL decreased in survivors, mostly in physical domains
Overall survival · 5 years
- 5-year overall survival rate
- 30%
- No significant difference between groups
Original publication
Long-Term Outcome of Severe Metabolic Acidemia in ICU Patients, a BICAR-ICU Trial Post Hoc Analysis. Crit Care Med. Published 8 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →